New research method to identify brain tumors could enhance neurosurgery

January 10, 2013
New Research Method to Identify Brain Tumors Could Enhance Neurosurgery
An artist’s depiction of the Stony Brook University Biomedical Engineering research team’s work identifying brain tumors is on the cover of Translational Oncology.

(Medical Xpress)—The use of a new brain tumor-targeting contrast agent that differentiates between normal and cancer cells in conjunction with a high-powered microscopy system could potentially lead to a method of more precise neurosurgery for brain tumors, according to research paper published as a cover story in the December issue of Translational Oncology. Developed by researchers in the Department of Biomedical Engineering (BME) at Stony Brook University, the contrast agent adheres to a molecular marker of medulloblastoma, a form of brain cancer, and can be seen by the optical microscope system, also developed by the research team.

In their article entitled "Microscopic Delineation of Medulloblastoma Margins in a Using a Topically Applied VEGFR-1 Probe," Stony Brook researchers Dr. Jonathan T.C. Liu, Assistant Professor of Biomedical Engineering, and BME graduate students Danni Wang, Steven Y. Leigh, and Ye Chen, and colleagues from Stanford University, created a contrast agent that adheres to vascular endothelial growth factor receptor 1 (VEGFR-1), which is overexpressed on the surface of many medulloblastoma cell lines and primary tissues. The team developed a VEGFR-1 chemical targeting agent that was topically applied to sample tissue.

Based on the research model, which confirmed cancerous tissue through histopathology, the team discovered that by using the contrast agent in conjunction with laser-scanning 3D microscopy, the optical contrast agent caused tumors to "glow"with fluorescence at each of the tumor margins. The process enabled the research team to define tumor margins, including residual .

Their approach may have significant implications in the surgical treatment of medulloblastoma because, the authors explain: "Bulk tumor resection remains the first line of treatment, where it has been shown that the completeness of tumor resection correlates strongly with the survival of patients. The goal of neurosurgeons is to maximize the removal of tumor while minimizing the removal of normal tissues.

New Research Method to Identify Brain Tumors Could Enhance Neurosurgery
Dr. Jonathan T.C. Liu, left, around a high-powered microscopy system in his Biomedical Engineering laboratory that is used to test a new brain-tumor targeting contrast agent, along with research team members and graduate students Danni Wang and Steven Leigh.

"The current gold standard for assessing malignancy is histopathology of biopsied tissue samples. However, this is rarely performed at the tumor margins during resection because of the time required for frozen sections to be prepared and interpreted by a pathologist. Furthermore, histopathology is expensive and requires the removal of brain tissue regardless of the state of the tissue."

"There is a great need for a noninvasive method to rapidly and accurately visualize residual malignancy to assist surgeons during the process, and we think that our research results provides a foundation and approach toward that ultimate goal," said Dr. Liu, Principal Investigator. "Our chemical probe with utilization of a microscope custom-built to view molecular protein biomarkers in three dimensions identifies tumor margins with accuracy that could potentially approach the gold standard of pathology based on tissue biopsies."

The authors said that next step in the research is to investigate the ability of the VEGFR-1 fluorescent probe, used in conjunction with their microscope and optical system, to enhance surgical resection in experimental models and ultimately in patients.

"We are also developing miniature microscopes, essentially hand-held devices with the same capability for three-dimensional imaging, which are designed to be an intraoperative guidance for neurosurgery," explained Dr. Liu.

To further advance this hand-held microscopy and imaging technology, Dr. Liu's team and colleagues at Memorial Sloan Kettering Cancer Center have received a three-year $2.4 million grant from the National Institute for Dental and Craniofacial Research to develop a miniature hand-held confocal microscope for early detection of oral cancers. Dr. Liu said the technology is based on an advanced confocal architecture to enable high speed microscopy of tissues and would be similarly developed for a hand-held microscope for neurosurgery.

More broadly, the research team believes that the combination of intraoperative confocal microscopy with molecularly targeted has the potential to serve as a valuable complement to current image-guided surgery approaches, such as those with MRI or CT, for resection of and other forms of cancer.

Explore further: New probe provides vital assist in brain cancer surgery

More information: … /v05i06/neo12277.pdf

Related Stories

New probe provides vital assist in brain cancer surgery

July 24, 2012
A new probe developed collaboratively at Norris Cotton Cancer Center and Dartmouth College's Thayer School of Engineering uses an innovative fluorescence-reading technology to help brain surgeons distinguish cancerous tissue ...

University Hospitals Seidman Cancer Center tests novel drug that makes brain tumors glow hot pink

December 1, 2011
Just 24 hours after Lisa Rek sang at her niece's wedding, her husband Brad was driving her to a local hospital.

A more accurate and noninvasive look at cancerous tumors

July 10, 2012
(Medical Xpress) -- Chao Zhou believes his work with combining imaging technologies has the potential to improve surgeries that remove malignant breast tumors.

Recommended for you

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.